Feature|Articles|November 18, 2026

Complicated UTI Care Strained by Unclear Goals, Access Gaps

Fact checked by: Maggie L. Shaw
Listen
0:00 / 0:00

Key Takeaways

  • Treatment goals for complicated UTI vary, particularly with chronic instrumentation, raising unresolved questions about whether endpoints should prioritize cultures, symptoms, mortality prevention, or complication avoidance.
  • Anatomic drivers are common; routine bladder scanning can reframe evaluation by identifying retention or structural contributors, rather than treating recurrent episodes as purely microbiologic failures.
SHOW MORE

Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.

Complicated urinary tract infection (UTI) sits at an awkward intersection of specialties, with definitions that vary by clinician and discharge options that depend as much on logistics as on pharmacology. As newer antibiotics reach the market, the question for health systems is less whether options exist than whether patients can reach them.

Eight clinicians took up that question on November 5, 2026, in Boston at a Population Health Roundtable hosted by The American Journal of Managed Care® (AJMC®). The discussion, which centered on complicated UTI, was moderated by Kalpana Gupta, MD, MPH, chief of infectious diseases at VA Boston Healthcare System and professor of medicine at Boston University Chobanian & Avedisian School of Medicine.

Clinicians Question What Treatment Is Meant to Achieve

Toby Chai, MD, chair of the Department of Urology at Chobanian & Avedisian and chief of urology at Boston Medical Center, questioned the end point of therapy in patients with catheters and nephrostomy tubes. He asked what clinicians were actually treating toward.

Participants

  • Toby Chai, MD — Chair, Department of Urology, Boston University Chobanian & Avedisian School of Medicine; Chief of Urology, Boston Medical Center
  • Eric Gillett, PharmD — Infectious Diseases Pharmacist, Brigham and Women's Hospital
  • Heidi Rayala, MD, PhD — Urologic Surgeon, Beth Israel Deaconess Medical Center
  • Judith Strymish, MD — Infectious Disease Clinician and Antibiotic Stewardship Lead, VA Boston Healthcare System

"What's the goal for me in treating a complicated UTI? Is it a sterile urine culture? . . . Is it symptom relief? Is it prevention of death? Is it prevention of complications?" Chai asked.

Heidi Rayala, MD, PhD, a urologic surgeon at Beth Israel Deaconess Medical Center, said bladder scanning had changed how she approached these cases. "I think that [a bladder scan] has been transformative, because I would argue the vast majority of people who are getting complicated UTIs have some type of anatomic underpinning," Rayala said.

Visibility after discharge was another gap. Asked how well clinicians knew what happened in outpatient care, Eric Gillett, PharmD, an infectious diseases pharmacist at Brigham and Women's Hospital, said, "I would say we don't know very well."

Getting Patients Home Depends on Capacity, Not Just Drugs

Patients ready for discharge often lacked a practical way to finish therapy, and Gillett said outpatient infusion capacity was limited.

"I feel like our outpatient infusion suites are devoted to oncology patients . . . They're not devoted to people who have infections," Gillett said.

Judith Strymish, MD, an infectious disease clinician and antibiotic stewardship lead at VA Boston Healthcare System, said placing thick lines for a couple of days of therapy seemed absurd to everybody. A transplant infectious disease specialist said outpatient parenteral therapy at their institution was reserved for patients expecting at least 2 weeks of intravenous therapy, so many stayed hospitalized for the final days.

Several panelists said they sometimes finished a course with a single aminoglycoside dose or an intramuscular injection.

Newer Agents Meet Prior Authorization and Stewardship Hurdles

Panelists saw potential for newer agents to keep patients out of the hospital, and oral tebipenem drew particular attention. Gupta presented data from PIVOT-PO (NCT06059846), which showed that the oral agent was noninferior to an intravenous comparator in complicated UTI.

Gillett said of tebipenem, “If it were readily available in the outpatient setting and well stewarded, it'd be really helpful for those patients." He expected it to be used mainly after discharge, with ertapenem used in the hospital because of cost.

An infectious disease physician said such agents were being underused. "I think they're underused because I think they're hard to access. I think we haven't devoted institutional resources to providing support to accessing them," the physician said.

Gillett said outpatient stewardship differed from inpatient oversight. "If somebody wants to use it, they can send a prescription, and there's not a whole lot you can do," he said.

Asked whether newer oral agents requiring paperwork would take hold in urology, Rayala answered, "I think if there's paperwork, no. We don't have the bandwidth."

Another infectious disease physician pointed to prior authorization as a barrier. "When you can't wait, the prior authorization process is probably going to be the real barrier, and we have limited control over that," the physician said.

Panel Looks to Shared Protocols and Real-Time Collaboration

The same physician said protocols for newer agents should include concrete information on how to access them and what clinicians could infer from available susceptibility testing. The transplant infectious disease specialist said better communication between hospitals would help, and Gillett said a multihospital group was drafting UTI guidance on the novel agents.

The infectious disease physician and medical director of infection control called for forums where clinicians could discuss specific inpatient cases across disciplines.

"Across the breadth of things that we manage, UTI don't get no respect," the physician said.


Related to this article